Not logged in Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials Horan, William P.; Kalali, Amir; Brannan, Stephen K.; Drevets, Wayne; Leoni, Matthew; Mahableshwarkar, Atul; Martin, William J.; Rao, Srinivas; Reuteman-Fowler, Corey; Sauder, Colin; Savitz, Adam; Singh, Jaskaran; Tiller, Jane; Walker, Gary; Wendland, Jens R.; Harvey, Philip D. Share Save
Response to Commentaries Horan, William P.; Kalali, Amir; Brannan, Stephen K.; Drevets, Wayne; Mahableshwarkar, Atul; Rao, Srinivas; Reuteman-Fowler, Corey; Savitz, Adam; Singh, Jaskaran; Walker, Gary; Wendland, Jens R.; Harvey, Philip D. Share Save
Share Save
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial Loebel, Antony; Cucchiaro, Josephine; Sarma, Kaushik; Xu, Lei; Hsu, Chuanchieh; Kalali, Amir H.; Pikalov, Andrei; Potkin, Steven G. Share Save
Share Save
Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study Meltzer, Herbert Y.; Cucchiaro, Josephine; Silva, Robert; Ogasa, Masaaki; Phillips, Debra; Xu, Jane; Kalali, Amir H.; Schweizer, Edward; Pikalov, Andrei; Loebel, Antony Share Save
Share Save
Share Save
LURASIDONE IN THE TREATMENT OF ACUTE SCHIZOPHRENIA: RESULTS OF THE DOUBLE-BLIND, PLACEBO-CONTROLLED PEARL 2 TRIAL Cucchiaro, Josephine; Silva, Robert; Ogasa, Masaaki; Xu, Jane; Phillips, Debra; Simonelli, Doreen; Kalali, Amir; Loebel, Antony; Meltzer, Herbert Share Save
Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia Canuso, Carla M.; Dirks, Bryan; Carothers, Jennifer; Kosik-Gonzalez, Colette; Bossie, Cynthia A.; Zhu, Young; Damaraju, C. V.; Kalali, Amir H.; Mahmoud, Ramy Share Save
Share Save
Share Save
What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It? Kemp, Aaron S.; Schooler, Nina R.; Kalali, Amir H.; Alphs, Larry; Anand, Ravi; Awad, George; Davidson, Michael; Dube, Sanjay; Ereshefsky, Larry; Gharabawi, Georges; Leon, Andrew C.; Lepine, Jean-Pierre; Potkin, Steven G.; Vermeulen, An Share Save
The depression inventory development workgroup: results from the second validation study Kalali, A.; Vaccarino, A.; Evans, K.; Kennedy, S.; Kobak, K.; Sills, T.; Sheehan, D.; Williams, J.; Greist, J.; Schatzberg, A. Share Save
The new GRID Hamilton Rating Scale for depression demonstrates excellent inter-rater reliability for inexperienced and experienced raters before and after training Tabuse, Hideaki; Kalali, Amir; Azuma, Hideki; Ozaki, Norio; Iwata, Nakao; Naitoh, Hiroshi; Higuchi, Teruhiko; Kanba, Shigenobu; Shioe, Kunihiko; Akechi, Tatsuo; Furukawa, Toshi A. Share Save
Share Save
Share Save
Extended-release carbamazepine capsules as monotherapy in bipolar disorder - Pooled results from two randomised, double-blind, placebo-controlled trials Weisler, RH; Hirschfeld, R; Cutler, AJ; Gazda, T; Ketter, TA; Keck, PE; Swann, A; Kalali, A Share Save
Why the Hamilton Depression Rating Scale endures Bech, P; Engelhardt, N; Evans, KR; Gibertini, M; Kalali, AH; Kobak, KA; Lipsitz, JD; Williams, JBW; Pearson, JD; Rothman, M Share Save
Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Not logged in.png){kind=icon}